No mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis

Kidney International

Volumn 64, Issue 2, 2003, Pages 509-518

  Peters, Harm ^a   Daig, Ute ^a   Martini, Sebastian ^a   Rückert, Matthias ^a   Schäper, Frank ^a   Liefeldt, Lutz ^a   Krämer, Stephanie ^a   Hans H Neumayer, ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Fibrosis; L Arginine; Nitric oxide; TGF

Indexed keywords

AGMATINE; ARGININE; FIBRONECTIN; MESSENGER RNA; MOLSIDOMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYAMINE; PROLINE; PROTEINASE INHIBITOR; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE OVEREXPRESSION; GLOMERULONEPHRITIS; GLOMERULUS; HISTOLOGY; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0038458762     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00112.x     Document Type: Article

References (39)

1. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. BORDER WA, OKUDA S, LANGUINO LR, et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371-374, 1990
3. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
4. REYES AA, KARL IE, KLAHR S: Role of arginine in health and in renal disease. Am J Physiol 267:F331-F346, 1994
5. KONE BC: Nitric oxide in renal health and disease. Am J Kidney Dis 30:311-333, 1997
6. NORIS M, REMUZZI G: Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians 111:602-610, 1999
7. PETERS H, BORDER WA, NOBLE NA: From rats to men: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14:1640-1650, 1999
8. BLANTZ RC, SATRIANO J, GABBAI F, KELLY C: Biological effects of arginine metabolites. Acta Physiol Scand 168:21-25, 2000
9. ISHIZUKA S, CUNARD R, POUCELL-HATTON S, et al: Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 11:2256-2264, 2000
10. PETERS H, BORDER WA, NOBLE NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57:922-1001, 2000
11. PETERS H, NOBLE NA, BORDER WA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1575-1583, 1998
12. NARITA I, BORDER WA, KETTELER M, NOBLE NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
13. BENIGNI A, ZOJA C, NORIS M, et al: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 33:746-753, 1999
14. RANGAN GK, WANG Y, HARRIS DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 12:1696-1705, 2001
15. ATTIA DM, NI ZN, BOER P, et al: Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int 61:1776-1787, 2002
16. FEELISCH M: The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 358:113-122,1998
17. WATANABE N, KAMEI S, OHKUBO A, et al: Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32:1551-1554, 1986
18. RENNARD SI, BERG R, MARTIN GR, et al: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205-214, 1980
19. RUETTEN H, ZABEL U, LINZ W, SCHMIDT HH: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 85:534-541, 1999
20. GREEN LC, WAGNER DA, GLOGOWSKI J, et al: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem 126:131-138, 1982
21. EBERHARDT W, BEEG T, BECK KF, et al: Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 57:59-69, 2000
22. SCHMIDT RJ, BAYLIS C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58:1261-1266, 2000
23. BARBUL A: Arginine: Biochemistry, physiology, and therapeutic implications. J Parenter Enteral Nutr 10:227-238, 1986
24. REYES AA, KARL IE, YATES J, KLAHR S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy. Kidney Int 45:782-787, 1994
25. BAYLIS C, VALLANCE P: Measurement of nitrite and nitrate levels in plasma and urine - What does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 7:59-62, 1998
26. ASHAB I, PEER G, BLUM M, et al: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47:1515-1521, 1995
27. CHEN PY, SANDERS PW: L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88:1559-1567, 1991
28. SHIHAB FS, YI H, BENNETT WM, ANDOH TF: Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 58:1174-1185, 2000
29. RISEIRO MO, ANTUNES E, MUSCARA MN, et al: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertens 26:150-155, 1995
30. WENZEL UO, WOLF G, THAISS F, et al: Renovascular hypertension does not influence repair of glomerular lesions induced by antithymocyte glomerulonephritis. Kidney Int 58:1135-1147, 2000
31. CRAVEN PA, STUDER RK, FELDER J, et al: Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46:671-681, 1997
32. OZTURK H, ALDEMIR M, BUYUKBAYRAM H, et al: The effects of the nitric oxide donor molsidomine prevent warm ischemia-reperfusion injury of the rat renal - A functional and histophatological study. Int Urol Nephrol 32:601-607, 2001
33. PETERS H, BORDER WA, NOBLE NA: L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 55:2264-2273, 1999
34. NOIRI E, PERESLENI T, MILLER F, GOLIGORSKY MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97:2377-2383, 1996
35. VOS IH, JOLES JA, SCHURINK M, et al: Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 391:31-38, 2000
36. WEINBERG JB, GRANGER DL, PISETSKY DS, et al: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 179:651-660, 1994
37. KASHEM A, ENDOH M, YANO N, et al: Expression of inducible-NOS in human glomerulonephritis: The possible source is infiltrating monocytes/macrophages. Kidney Int 50:392-399, 1996
38. PETERS H, BORDER WA, RÜCKERT M, et al: L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int, 63:1382-1392, 2003
39. DE NICOLA L, BELLIZZI V, MINUTOLO R, et al: Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int 56:674-684, 1999